Back

Inhibition of nonsense-mediated decay rescues functional p53β/γ isoforms in MDM2-amplified cancers

Gudikote, J. P.; Cascone, T.; Poteete, A.; Sitthideatphaiboon, P.; Wu, Q.; Morikawa, N.; Zhang, F.; Peng, S.; Tong, P.; Li, L.; Shen, L.; Nilsson, M.; Jones, P.; Sulman, E. P.; Wang, J.; Bourdon, J.-C.; Johnson, F. M.; Heymach, J.

2020-04-07 cancer biology
10.1101/2020.04.06.026955 bioRxiv
Show abstract

Common mechanisms for p53 loss in cancer include expression of MDM2 or the human papilloma virus (HPV)-encoded E6 protein which both mediate degradation of wild-type (WT) p53 (p53). Here, we show that two alternatively-spliced, functional, truncated isoforms of p53 (p53{beta} and p53{gamma}, containing exons 1-9 of the p53 gene) can be markedly upregulated by pharmacologic or genetic inhibition of nonsense mediated decay (NMD), a regulator of aberrant mRNA stability. These isoforms lack the MDM2 binding domain and hence have reduced susceptibility to MDM2-mediated degradation. In MDM2-overexpressing cells bearing wildtype TP53 gene, NMD blockade increased p53{beta}/{gamma} expression and p53 pathway activation, enhanced radiosensitivity, and inhibited tumor growth. A similar pattern was observed in HPV+ cancer cells and in cancer cells with p53 mutations downstream of exon 9. These results identify a novel therapeutic strategy for restoration of p53 function in tumors rendered p53 deficient through MDM2 overexpression, HPV infection, or certain p53 mutations.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Oncogene
76 papers in training set
Top 0.1%
17.2%
2
Cancer Research
116 papers in training set
Top 0.1%
14.5%
3
Clinical Cancer Research
58 papers in training set
Top 0.2%
7.0%
4
Cell Reports
1338 papers in training set
Top 8%
6.3%
5
eLife
5422 papers in training set
Top 23%
3.9%
6
Molecular Cancer Therapeutics
33 papers in training set
Top 0.2%
3.5%
50% of probability mass above
7
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 23%
3.0%
8
JCI Insight
241 papers in training set
Top 2%
2.7%
9
Nature Communications
4913 papers in training set
Top 45%
2.6%
10
Journal of Experimental Medicine
106 papers in training set
Top 1%
2.6%
11
Molecular Cancer Research
42 papers in training set
Top 0.2%
2.1%
12
EMBO Molecular Medicine
85 papers in training set
Top 1%
2.0%
13
Cancer Research Communications
46 papers in training set
Top 0.3%
1.9%
14
Cancers
200 papers in training set
Top 3%
1.7%
15
Nucleic Acids Research
1128 papers in training set
Top 12%
1.5%
16
Cancer Cell
38 papers in training set
Top 1%
1.3%
17
Cell Reports Medicine
140 papers in training set
Top 5%
1.2%
18
Science Signaling
55 papers in training set
Top 0.2%
1.2%
19
Genes & Development
90 papers in training set
Top 0.8%
1.2%
20
Cell Chemical Biology
81 papers in training set
Top 3%
1.1%
21
Cell Death & Differentiation
48 papers in training set
Top 0.5%
0.9%
22
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
23
Molecular Therapy
71 papers in training set
Top 2%
0.9%
24
Cancer Discovery
61 papers in training set
Top 2%
0.9%
25
NAR Cancer
36 papers in training set
Top 0.1%
0.9%
26
Cancer Letters
32 papers in training set
Top 0.8%
0.7%
27
Science Advances
1098 papers in training set
Top 32%
0.7%
28
Molecular Cell
308 papers in training set
Top 11%
0.6%
29
Communications Biology
886 papers in training set
Top 30%
0.6%
30
EMBO Reports
88 papers in training set
Top 1%
0.6%